{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:46:28Z","timestamp":1792788388986,"version":"4.5.0"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Backgroun<\/jats:title>\n                  <jats:p>Sympathetic overactivation is associated with numerous pathologies, including arterial hypertension, diabetes, metabolic syndrome and chronic kidney disease (CKD). Renal denervation (RDN) has emerged as an adjacent therapy for the management of hypertension. By modulating sympathetic activity in the whole body, RDN has shown conflicting results regarding insulin secretion and glucose homeostasis. The aim of this study is to analyse the impact of RDN on glycaemic control in patients with CKD.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A total of 155 hypertensive patients with (n\u00a0=\u00a045) or without CKD (n\u00a0=\u00a0110) were included in this post hoc analysis. All patients underwent radiofrequency-, ultrasound- or alcohol injection\u2013based RDN. Fasting plasma glucose (FPG) and haemoglobin A1c levels were measured at baseline, 3\u00a0months and 6\u00a0months after RDN in parallel with the office and 24-h ambulatory blood pressure. CKD was defined either by clinical diagnosis, an estimated glomerular filtration rate (eGFR) of 15\u201359\u00a0ml\/min\/1.73\u00a0m2 and\/or A2\/A3 albuminuria in hypertensive patients, repeatedly confirmed, or several of these criteria.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In the total study cohort, FPG decreased by 5.1\u00a0\u00b1\u00a029.1\u00a0mg\/dl (P\u00a0=\u00a0.032) and by 7.9\u00a0\u00b1\u00a032.7\u00a0mg\/dl (P\u00a0=\u00a0.003) at 3 and 6\u00a0months after RDN, respectively. The change in FPG levels was related to the change in 24-h systolic BP (r\u00a0=\u00a00.286, P\u00a0=\u00a0.008) 3\u00a0months after RDN. Among patients with CKD, FPG levels decreased by 13.5\u00a0\u00b1\u00a043.5\u00a0mg\/dl at 3\u00a0months (P\u00a0=\u00a0.043) and by 17.1\u00a0\u00b1\u00a045.2\u00a0mg\/dl at 6\u00a0months (P\u00a0=\u00a0.015) following RDN. These reductions were greater compared with the non-CKD group (P\u00a0=\u00a0.021 and P\u00a0=\u00a0.024, respectively). After excluding patients on oral antidiabetic or insulin therapy, patients with CKD (but not those without CKD) exhibited a reduction in FPG levels of 6.7\u00a0\u00b1\u00a015.3\u00a0mg\/dl (P\u00a0=\u00a0.043) at 6\u00a0months post-RDN. No significant changes were observed in eGFR in either group.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>We observed that FPG levels improved to a greater extent in hypertensive patients with CKD after RDN. Thus RDN may have a broader therapeutic impact beyond blood pressure reduction in CKD patients.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ckj\/sfaf184","type":"journal-article","created":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T16:14:47Z","timestamp":1751040887000},"source":"Crossref","is-referenced-by-count":6,"title":["Effect of renal denervation on glucose metabolism in hypertensive patients with and without chronic kidney disease"],"prefix":"10.1093","volume":"18","author":[{"given":"Venera","family":"Bytyqi","sequence":"first","affiliation":[{"name":"University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg Department of Nephrology and Hypertension, , Erlangen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Kannenkeril","sequence":"additional","affiliation":[{"name":"University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg Department of Nephrology and Hypertension, , Erlangen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Schmid","sequence":"additional","affiliation":[{"name":"Institute of Radiology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg , Erlangen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Striepe","sequence":"additional","affiliation":[{"name":"University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg Department of Nephrology and Hypertension, , Erlangen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6952-4660","authenticated-orcid":false,"given":"Agnes","family":"Bosch","sequence":"additional","affiliation":[{"name":"University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg Department of Nephrology and Hypertension, , Erlangen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina V","family":"Karg","sequence":"additional","affiliation":[{"name":"University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg Department of Nephrology and Hypertension, , Erlangen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Schiffer","sequence":"additional","affiliation":[{"name":"University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg Department of Nephrology and Hypertension, , Erlangen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Uder","sequence":"additional","affiliation":[{"name":"Institute of Radiology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg , Erlangen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland E","family":"Schmieder","sequence":"additional","affiliation":[{"name":"University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg Department of Nephrology and Hypertension, , Erlangen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,6,18]]},"reference":[{"issue":"Suppl 2","key":"2025070404570326300_bib1","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1097\/00005344-199512020-00004","article-title":"Sympathetic nervous system: contribution to human hypertension and related cardiovascular diseases","volume":"26","author":"Esler","year":"1995","journal-title":"J Cardiovasc Pharmacol"},{"key":"2025070404570326300_bib2","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1161\/01.HYP.34.4.724","article-title":"Sympathetic activation in the pathogenesis of hypertension and progression of organ damage","volume":"34","author":"Mancia","year":"1999","journal-title":"Hypertension"},{"key":"2025070404570326300_bib3","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1152\/physrev.00007.2009","article-title":"Sympathetic nervous system overactivity and its role in the development of cardiovascular disease","volume":"90","author":"Malpas","year":"2010","journal-title":"Physiol Rev"},{"key":"2025070404570326300_bib4","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1152\/japplphysiol.00182.2010","article-title":"Point: chronic activation of the sympathetic nervous system is the dominant contributor to systemic hypertension","volume":"109","author":"Esler","year":"2010","journal-title":"J Appl Physiol"},{"key":"2025070404570326300_bib5","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1152\/japplphysiol.00832.2009","article-title":"The 2009 Carl Ludwig Lecture: Pathophysiology of the human sympathetic nervous system in cardiovascular diseases: the transition from mechanisms to medical management","volume":"108","author":"Esler","year":"2010","journal-title":"J Appl Physiol"},{"key":"2025070404570326300_bib6","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1111\/nyas.14217","article-title":"Effects of sympathetic modulation in metabolic disease","volume":"1454","author":"Carnagarin","year":"2019","journal-title":"Ann NY Acad Sci"},{"key":"2025070404570326300_bib7","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S0895-7061(96)00303-2","article-title":"Sympathetic nerve hyperactivity precedes hyperinsulinemia and blood pressure elevation in a young, nonobese Japanese population","volume":"10","author":"Masuo","year":"1997","journal-title":"Am J Hypertens"},{"key":"2025070404570326300_bib8","doi-asserted-by":"publisher","first-page":"4104","DOI":"10.1161\/01.CIR.96.11.4104","article-title":"Insulin as a vascular and sympathoexcitatory hormone: implications for blood pressure regulation, insulin sensitivity, and cardiovascular morbidity","volume":"96","author":"Scherrer","year":"1997","journal-title":"Circulation"},{"key":"2025070404570326300_bib9","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1161\/01.CIR.0000103123.66264.FE","article-title":"Impact of type 2 diabetes mellitus on sympathetic neural mechanisms in hypertension","volume":"108","author":"Huggett","year":"2003","journal-title":"Circulation"},{"key":"2025070404570326300_bib10","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.pharmthera.2010.02.002","article-title":"Sympathetic nervous activation in obesity and the metabolic syndrome\u2014causes, consequences and therapeutic implications","volume":"126","author":"Lambert","year":"2010","journal-title":"Pharmacol Ther"},{"key":"2025070404570326300_bib11","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3389\/fphys.2012.00010","article-title":"Effects of renal denervation on sympathetic activation, blood pressure, and glucose metabolism in patients with resistant hypertension","volume":"3","author":"Schlaich","year":"2012","journal-title":"Front Physiol"},{"key":"2025070404570326300_bib12","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1056\/NEJMc0904179","article-title":"Renal sympathetic-nerve ablation for uncontrolled hypertension","volume":"361","author":"Schlaich","year":"2009","journal-title":"N Engl J Med"},{"key":"2025070404570326300_bib13","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1016\/S0140-6736(18)30951-6","article-title":"Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial","volume":"391","author":"Kandzari","year":"2018","journal-title":"Lancet"},{"key":"2025070404570326300_bib14","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1111\/jch.13827","article-title":"Efficacy and safety of renal denervation for the management of arterial hypertension: a systematic review and meta-analysis of randomized, sham-controlled, catheter-based trials","volume":"22","author":"Stavropoulos","year":"2020","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"2025070404570326300_bib15","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s00592-023-02208-7","article-title":"Unravelling the effect of renal denervation on glucose homeostasis: more questions than answers?","volume":"61","author":"Koutra","year":"2024","journal-title":"Acta Diabetol"},{"key":"2025070404570326300_bib16","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1161\/CIRCULATIONAHA.110.991869","article-title":"Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study","volume":"123","author":"Mahfoud","year":"2011","journal-title":"Circulation"},{"key":"2025070404570326300_bib17","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1161\/HYPERTENSIONAHA.114.04798","article-title":"Denervation of the renal arteries in metabolic syndrome: the DREAMS-study","volume":"65","author":"Verloop","year":"2015","journal-title":"Hypertension"},{"key":"2025070404570326300_bib18","doi-asserted-by":"publisher","first-page":"2164","DOI":"10.2337\/db16-0205","article-title":"Renal denervation for resistant hypertension fails to improve insulin resistance as assessed by hyperinsulinemic-euglycemic step clamp","volume":"65","author":"Miroslawska","year":"2016","journal-title":"Diabetes"},{"key":"2025070404570326300_bib19","first-page":"109","article-title":"One year follow-up effect of renal sympathetic denervation in patients with resistant hypertension","volume":"12","author":"Pourmoghaddas","year":"2016","journal-title":"ARYA Atheroscler"},{"key":"2025070404570326300_bib20","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","article-title":"2023 ESH guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA)","volume":"41","author":"Mancia","year":"2023","journal-title":"J Hypertens"},{"key":"2025070404570326300_bib21","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1016\/S0140-6736(17)32281-X","article-title":"Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial","volume":"390","author":"Townsend","year":"2017","journal-title":"Lancet"},{"key":"2025070404570326300_bib22","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1016\/S0140-6736(18)31082-1","article-title":"Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial","volume":"391","author":"Azizi","year":"2018","journal-title":"Lancet"},{"key":"2025070404570326300_bib23","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1016\/S0140-6736(21)00788-1","article-title":"Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial","volume":"397","author":"Azizi","year":"2021","journal-title":"Lancet"},{"key":"2025070404570326300_bib24","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ahj.2021.05.015","article-title":"Catheter-based alcohol-mediated renal denervation for the treatment of uncontrolled hypertension: design of two sham-controlled, randomized, blinded trials in the absence (TARGET BP OFF-MED) and presence (TARGET BP I) of antihypertensive medications","volume":"239","author":"Mahfoud","year":"2021","journal-title":"Am Heart J"},{"key":"2025070404570326300_bib25","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.jcin.2019.10.048","article-title":"Alcohol-mediated renal denervation using the Peregrine System Infusion Catheter for treatment of hypertension","volume":"13","author":"Mahfoud","year":"2020","journal-title":"JACC Cardiovasc Interv"},{"key":"2025070404570326300_bib26","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.2337\/diabetes.48.5.1093","article-title":"Metabolic and hemodynamic effects of moxonidine in the Zucker diabetic fatty rat model of type 2 diabetes","volume":"48","author":"Yakubu-Madus","year":"1999","journal-title":"Diabetes"},{"key":"2025070404570326300_bib27","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.numecd.2012.09.004","article-title":"Renal denervation in cardiometabolic disease: concepts, achievements and perspectives","volume":"23","author":"Grassi","year":"2013","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"2025070404570326300_bib28","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.3390\/ijms18081682","article-title":"Sympathetic overactivity in chronic kidney disease: consequences and mechanisms","volume":"18","author":"Kaur","year":"2017","journal-title":"Int J Mol Sci"},{"key":"2025070404570326300_bib29","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s001250051341","article-title":"New insights into sympathetic regulation of glucose and fat metabolism","volume":"43","author":"Nonogaki","year":"2000","journal-title":"Diabetologia"},{"key":"2025070404570326300_bib30","doi-asserted-by":"publisher","first-page":"3372","DOI":"10.1016\/j.jacc.2018.09.075","article-title":"Secretory capacity of pancreatic beta-cells is enhanced 6 months after renal denervation in hypertensive patients","volume":"72","author":"Ott","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2025070404570326300_bib31","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/j.1440-1797.2011.01517.x","article-title":"Assessment of markers of glycaemic control in diabetic patients with chronic kidney disease using continuous glucose monitoring","volume":"17","author":"Vos","year":"2012","journal-title":"Nephrology"},{"key":"2025070404570326300_bib32","doi-asserted-by":"publisher","first-page":"107707","DOI":"10.1016\/j.jdiacomp.2020.107707","article-title":"Diabetes mellitus in chronic kidney disease: biomarkers beyond HbA1c to estimate glycemic control and diabetes-dependent morbidity and mortality","volume":"34","author":"Copur","year":"2020","journal-title":"J Diabetes Complications"},{"key":"2025070404570326300_bib33","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1161\/HYPERTENSIONAHA.114.05010","article-title":"First report of the Global SYMPLICITY Registry on the effect of renal artery denervation in patients with uncontrolled hypertension","volume":"65","author":"B\u00f6hm","year":"2015","journal-title":"Hypertension"},{"key":"2025070404570326300_bib34","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1093\/ndt\/gfab154","article-title":"Renal denervation in patients with versus without chronic kidney disease: results from the Global SYMPLICITY Registry with follow-up data of 3 years","volume":"37","author":"Ott","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"2025070404570326300_bib35","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/jch.12724","article-title":"Long-term effects of renal sympathetic denervation on hypertensive patients with mild to moderate chronic kidney disease","volume":"18","author":"Kiuchi","year":"2016","journal-title":"J Clin Hypertens"},{"key":"2025070404570326300_bib36","doi-asserted-by":"publisher","first-page":"sfad237","DOI":"10.1093\/ckj\/sfad237","article-title":"Blood pressure reduction after renal denervation in patients with or without chronic kidney disease","volume":"17","author":"G\u00fcnes-Altan","year":"2024","journal-title":"Clin Kidney J"},{"key":"2025070404570326300_bib37","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1161\/CIRCULATIONAHA.124.069709","article-title":"Effects of catheter-based renal denervation in hypertension: a systematic review and meta-analysis","volume":"150","author":"Vukadinovi\u0107","year":"2024","journal-title":"Circulation"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfaf184\/63521203\/sfaf184.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/18\/7\/sfaf184\/63521203\/sfaf184.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/18\/7\/sfaf184\/63521203\/sfaf184.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T08:57:09Z","timestamp":1751619429000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/doi\/10.1093\/ckj\/sfaf184\/8168209"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,18]]},"references-count":37,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7,2]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfaf184","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7]]},"published":{"date-parts":[[2025,6,18]]},"article-number":"sfaf184"}}